"Hodgkin Disease" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
| Descriptor ID |
D006689
|
| MeSH Number(s) |
C04.557.386.355 C15.604.515.569.355 C20.683.515.761.355
|
| Concept/Terms |
Hodgkin Disease- Hodgkin Disease
- Disease, Hodgkin
- Granuloma, Hodgkin's
- Hodgkin's Granuloma
- Granuloma, Hodgkins
- Hodgkins Granuloma
- Lymphogranuloma, Malignant
- Lymphogranulomas, Malignant
- Malignant Lymphogranuloma
- Malignant Lymphogranulomas
- Hodgkin Lymphoma
- Lymphoma, Hodgkin
- Hodgkin's Disease
- Disease, Hodgkin's
- Hodgkin's Lymphoma
- Hodgkins Lymphoma
- Lymphoma, Hodgkin's
- Hodgkins Disease
- Disease, Hodgkins
- Granuloma, Hodgkin
- Hodgkin Granuloma
- Granuloma, Malignant
- Malignant Granuloma
- Malignant Granulomas
|
Below are MeSH descriptors whose meaning is more general than "Hodgkin Disease".
Below are MeSH descriptors whose meaning is more specific than "Hodgkin Disease".
This graph shows the total number of publications written about "Hodgkin Disease" by people in this website by year, and whether "Hodgkin Disease" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 1 | 0 | 1 |
| 2015 | 1 | 1 | 2 |
| 2023 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hodgkin Disease" by people in Profiles.
-
Management of limited-stage Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2023 Dec 08; 2023(1):500-509.
-
Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes. Haematologica. 2023 11 01; 108(11):3025-3032.
-
Efficacy of a survivorship-focused consultation versus a time-controlled rehabilitation consultation in patients with lymphoma: A cluster randomized controlled trial. Cancer. 2018 12 01; 124(23):4567-4576.
-
Germline variation of TNFAIP3 in primary Sjögren's syndrome-associated lymphoma. Ann Rheum Dis. 2016 Apr; 75(4):780-3.
-
Serum ferritin as prognostic marker in classical Hodgkin lymphoma treated with ABVD-based therapy. Leuk Lymphoma. 2015; 56(11):3096-102.
-
Severe infusion reactions to brentuximab vedotin in two patients with Hodgkin lymphoma previously treated with allogeneic stem cell transplantation. J Oncol Pharm Pract. 2013 Sep; 19(3):279-83.
-
Composite hodgkin and non-hodgkin lymphoma of the mitral and aortic valves. J Am Soc Echocardiogr. 2010 Oct; 23(10):1113.e5-7.
-
Radiolabeling of antibodies for therapy and diagnosis. Methods Mol Biol. 1995; 51:423-39.
-
Optic neuropathy in Hodgkin's disease. Am J Ophthalmol. 1992 Nov 15; 114(5):625-9.
-
[Cervical pain revealing Hodgkin's disease. Apropos of a case]. Rev Rhum Mal Osteoartic. 1992 Oct; 59(9):593-4.